在接下来2年的临床随访中，均无支架内血栓形成。
No stent thrombosis was observed in any of the patients within 2 years of clinical follow-up.
在接下来2年的临床随访中，阿尔法支架组均没有发现支架内血栓形成。
No stent thrombosis was observed in the Alpha stent group within 2 years of clinical follow-up.
现对药物涂层支架内血栓形成的相关临床证据和病理生理机制，特别是药物涂层支架本身在其中的作用进行综述。
This article reviews the clinical evidence and pathophysiological mechanisms of stent thrombosis of drug-eluting stent, especially the role of the stent itself in it.
目的：探讨ST段抬高性心肌梗死患者经皮冠状动脉介入置入雷帕霉素药物洗脱支架内血栓形成的相关因素及预后。
Objective to study the related factors and prognosis of rapamycin drug-eluting stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
目的：探讨糖尿病合并冠心病老年患者支架植入术后三联抗血小板治疗对预防支架内血栓形成和再狭窄的有效性及安全性。
Objective: To investigate the safety and efficacy of triple antiplatelet therapy in aged patients with diabetes mellitus combined with coronary heart disease after percutaneous coronary intervention.
目前，对于接受药物洗脱支架的患者，我们尝试维持双重抗血小板治疗在一年以上，因为我们非常关注晚期支架内血栓形成的可能性。
Right now, we try to keep dual anti-platelet therapy going for up to one year in patients who have a drug-eluting stent because we are very concerned about the possibility of late-stent thrombosis.
这篇文章中说，对于药物洗脱支架置入的患者，支架内血栓形成是和早期停用抗血小板紧密相关的主要副作用，其死亡率为20%到50%。
The paper says that stent thrombosis is the "leading adverse event" associated with early antiplatelet discontinuation in patients with DES and carries a mortality rate of 20-45%.
人们期望这一特性可以加速愈合过程，防止血栓形成，并尽量减少动脉支架内狭窄。
It is hoped that this unique characteristic will accelerate the healing process, protect against blood clot formation, and minimize restenosis in stented arteries.
人们期望这一特性可以加速愈合过程，防止血栓形成，并尽量减少动脉支架内狭窄。
It is hoped that this unique characteristic will accelerate the healing process, protect against blood clot formation, and minimize restenosis in stented arteries.
应用推荐